GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DMS Imaging SA (FRA:AS0) » Definitions » Retained Earnings

DMS Imaging (FRA:AS0) Retained Earnings : €-0.71 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is DMS Imaging Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. DMS Imaging's retained earnings for the quarter that ended in Dec. 2023 was €-0.71 Mil.

DMS Imaging's quarterly retained earnings increased from Dec. 2022 (€-5.58 Mil) to Jun. 2023 (€0.73 Mil) but then declined from Jun. 2023 (€0.73 Mil) to Dec. 2023 (€-0.71 Mil).

DMS Imaging's annual retained earnings declined from Dec. 2021 (€-0.21 Mil) to Dec. 2022 (€-5.58 Mil) but then increased from Dec. 2022 (€-5.58 Mil) to Dec. 2023 (€-0.71 Mil).


DMS Imaging Retained Earnings Historical Data

The historical data trend for DMS Imaging's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMS Imaging Retained Earnings Chart

DMS Imaging Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -58.89 -60.05 -0.21 -5.58 -0.71

DMS Imaging Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.21 -4.01 -5.58 0.73 -0.71

DMS Imaging Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


DMS Imaging  (FRA:AS0) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


DMS Imaging (FRA:AS0) Business Description

Traded in Other Exchanges
Address
7 Rue des Chasseurs Ardennais, Liege, BEL, 4031
DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

DMS Imaging (FRA:AS0) Headlines

No Headlines